Canadian Cancer Survivor Network – 13 nov. 2015. In this webinar: Discussion on biologics, including an explanation of the high level of precision that is required to produce a consistent biological product each time. Discussion on the growing interest in biosimilars, followed by what we can learn from Europe’s experience. Health Canada’s position on biosimilars, discussion on key issues surrounding biosimilars relevant to the Canadian market. The importance of patient safety and patient choice.
